N/A
N=70
Impact of Skin to Skin Contact on Maternal Satisfaction, Pain Scores, and Narcotic Usage After Cesarean Delivery
Skin to Skin Contact in Cesarean Deliveries
Bottom Line
View on ClinicalTrials.gov: NCT02533167 ↗Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Aug 2018
Primary outcome: Primary: Maternal Evoked Pain Scores — 43.55 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- skin to skin (Other)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Wake Forest University Health Sciences
- Primary completion
- Dec 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maternal Evoked Pain Scores |
43.55 | — |
Summary
Early skin to skin contact has beneficial effects and is part of the Healthy Birth Initiative. Positive effects on breast feeding, cardiorespiratory status, blood glucose control, and temperature has been demonstrated. It is the standard of care for vaginal deliveries but surgery is a barrier in its initiation in the operating room. This study is evaluating initiating skin to skin contact as soon as feasible in the operating room. Informed consent will be obtained from scheduled/non emergent cesarean sections who are of EGA.37 weeks who are ASA I-II and receiving the standard spinal anesthetic. Skin to skin contact will be initiated after delivery as soon as apgars and newborn assessment has been completed. Goal is a minimum of 60 minutes of skin to skin contact between the mother and the newborn, with the only interruption being upon movement from the OR table to the stretcher when leaving the OR. Subjects seen post delivery day 1 for assessments of pain and maternal satisfaction utilizing a sliding 100mm VAS assessment tool.
Eligibility Criteria
Inclusion Criteria
- non emergent cesarean deliveries term gestation age ASA I or II spinal anesthetic
Exclusion Criteria
- contraindication to spinal anesthetic or to medications utilized emergence cesarean delivery under age 18 less than 37 weeks gestational age
Data sourced from ClinicalTrials.gov (NCT02533167). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.